Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of B10-FC in Healthy Volunteers and COVID-19 Patients
NCT07156864Phase 1Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of B10-FC in coronavirus disease 2019 (COVID-19) (4 arms). Primary endpoint: Occurrence of adverse events at 28 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
B10-FC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07156864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156864.